A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience

dc.contributor.author	Cekdemir, Demet
dc.contributor.author	Guvenc, Serkan
dc.contributor.author	Ozdemirkiran, Fusun
dc.contributor.author	Eser, Ali
dc.contributor.author	Topts, Tayfur
dc.contributor.author	Ozkocaman, Vildan
dc.contributor.author	Sahin, Handan Haydaroglu
dc.contributor.author	Turak, Esra Ermis
dc.contributor.author	Esen, Ramazan
dc.contributor.author	Comert, Melda
dc.contributor.author	Sadrilo, Sevil
dc.date.accessioned	2021-12-21T08:48:00Z
dc.date.available	2021-12-21T08:48:00Z
dc.date.issued	2019
dc.identifier.issn	1300-7777
dc.identifier.issn	1308-5263
dc.identifier.uri	https://doi.org/10.4274/tjh.galenos.2019.2018.0307
dc.identifier.uri	http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/2336
dc.description.abstract	Objective: The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP). Materials and Methods: A total of 285 chronic ITP patients (18
dc.language.iso	English
dc.publisher	Galenos Yayıncılık
dc.rights	gold, Green Published
dc.title	A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience
dc.type	Article
dc.relation.journal	Turkısh Journal Of Hematology
dc.identifier.issue	4
dc.identifier.startpage	230
dc.identifier.endpage	237
dc.identifier.volume	36
dc.identifier.doi	10.4274/tjh.galenos.2019.2018.0307
dc.relation.issue	4
dc.relation.volume	36